Nkarta, Inc. · NASDAQ:NKTX
Nkarta — ACR Convergence 2026
28 slides from Nkarta's conference presentation, Nov 9, 2026
Slide 1: Initial Clinical Data in Myositis and Systemic Sclerosis
Initial Clinical Data in Myositis and Systemic Sclerosis ACR Convergence | November 9, 2026 NKX019 in Autoimmune Disease
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the company that are based on current expectations, estimates, forecasts, and projections ab
Slide 3: Three Nkarta Scientific Presentations at ACR Convergence 2026
Three Nkarta Scientific Presentations at ACR Convergence 2026 Guillermo Valenzuela, MD, FACR Dinesh Khanna, MBBS, MSc Preliminary Safety, PK/PD, and Clinical Activity of NKX019, an Allogeneic, CD19-Targeted, CAR NK Cell Therapy, in Systemic Sclerosis: Results From an Ongoing, Phase 1/2, Open-Label,
Slide 4: Agenda
Agenda Introduction & Overview Paul Hastings, CEO Clinical & Translational Data Shawn Rose, MD, PhD, CMO and Head of R&D Opportunity & Next Steps Nadir Mahmood, PhD, President Summary and Q&A Paul Hastings, CEO
Slide 5: Advantages of NKX019
Advantages of NKX019 An Off-the-Shelf, On-Demand, Allogeneic, CD19-Targeting CAR NK Cell Therapy On demand using healthy donor-derived NK cells Outpatient administration in community setting No need for hospitalization or overnight monitoring Rheumatologist directs care, not a cancer specialist Abil
Slide 6: Dose-dependent exposure and opportunity to enhance activity with compressed schedule
Dose-dependent exposure, plus an opportunity to enhance activity with a compressed schedule Data as of September 18, 2026. All patients received lymphodepletion (LD) preconditioning with fludarabine/cyclophosphamide (Flu/Cy) and NKX019 infusions on Days 0, 3, and 7. Gray lines show individual patien
Slide 7: Clinical & Translational Data
Clinical & Translational Data
Slide 8: NKX019 for autoimmune disease: dose response, delivered outpatient
NKX019 for autoimmune disease: dose response, delivered outpatient *LD preconditioning = a total of 90 mg/m2 Flu as 30 mg/m2/day on Days −5, −4, and −3 and 1 g/m2/day Cy on Day −3. Patients with cytopenia may receive Cy alone as 1 g/m2 Cy on Day –3. LD preconditioning is performed in an outpatient s
Slide 9: Overall Safety
Overall Ntrust Safety nkarta
Slide 10: NKX019 caused no treatment discontinuations or deaths in patients
NKX019 caused no treatment discontinuations or deaths in 40 patients Measure, n (%) Overall N = 40 Disease Indications SSc n = 15 IIM n = 13 LN n = 6 AAV n = 1 RA n = 5 Any TEAEs*,† 34 (85.0) 13 (86.7) 10 (76.9) 6 (100) 1 (100) 4 (80.0) Grade ≥3 events 14 (35.0) 5 (33.3) 4 (30.8) 5 (83.3) 0 0 Anemia
Slide 11: NKX019: a differentiated safety profile built for autoimmune disease
NKX019: a differentiated safety profile built for autoimmune disease NKX019 caused no cases of CRS, ICANS, IEC-HS, or GVHD across all indications Data as of September 18, 2026. 28, 7, and 5 patients in this analysis were enrolled, received LD preconditioning, and received at least 1 dose of NKX019 a
Slide 12: Myositis Results
Myositis Results nkarta
Slide 13: Myositis patients had active, treatment-refractory disease at baseline
Myositis patients had active, treatment-refractory disease at baseline Data as of September 18, 2026. Includes patients who received Fludarabine/Cyclophosphamide LD preconditioning and 3 doses of NKX019 and had at least 1 post‑baseline efficacy-evaluable assessment. *At screening prior to LD precond
Slide 14: IIM patients at 4B cells/dose achieved moderate-to-major TIS response
At 4B cells/dose, 5 of 6 IIM patients (83.3%) with ≥3 months of follow-up achieved a moderate-to-major TIS response 4B responses spanned three subtypes and were more consistent relative to lower doses NKX019 4B Cells/Dose NKX019 1B and 2B Cells/Dose Data as of September 18, 2026. TIS was evaluated i
Slide 15: IIM patients at 4B cells/dose achieved increases in MMT-8 score
At 4B cells/dose, 5 of 6 IIM patients (83.3%) with ≥3 months of follow-up achieved increases in their MMT-8 score Data as of September 18, 2026. MMT-8 was evaluated in patients who received LD preconditioning and 3 doses of NKX019 and had at least 1 post‑baseline efficacy-evaluable assessment. Open
Slide 16: Treatment with NKX019 in myositis led to reductions in CDASI-A
Treatment with NKX019 in myositis led to reductions in CDASI-A NKX019 1B and 4B Cells/Dose 4 of 8 (50.0%) patients receiving 4B cells/dose achieved clinically relevant reductions in CDASI-A, with 4 patients remaining relatively stable compared to baseline Data as of September 18, 2026. CDASI-A was e
Slide 17: Systemic Sclerosis Results
Systemic Sclerosis Results nkarta
Slide 18: SSc patients had long-standing disease and extensive prior therapy at baseline
SSc patients treated with NKX019 had long-standing disease and extensive prior therapy at baseline Data as of September 18, 2026. Includes patients who received Fludarabine/Cyclophosphamide LD preconditioning and 3 doses of NKX019 and had at least 1 post‑baseline efficacy-evaluable assessment. *From
Slide 19: Rapid and deep skin responses at 4B cells/dose
Rapid and deep responses in skin were observed through Day 90 in patients receiving 4B cells/dose Data as of September 18, 2026. Axis breaks were applied as needed for visualization purposes; no data points were excluded. Open circles indicate visits where administration of additional immunomodulato
Slide 20: SSc patients at 4B cells/dose achieved rCRISS-50 by Day 90
5 of 7 (71.4%) SSc patients at 4B cells/dose achieved rCRISS-50 by Day 90 Data as of September 18, 2026. An rCRISS response required improvement in ≥2 of 5 (2/5) or ≥3 of 5 (3/5) measures. *Denotes patients with ILD. †Indicates visits where administration of additional immunomodulatory agents (cDMAR
Slide 21: Translational Data
Translational Data nkarta
Slide 22: B cell nadir reached by Days 3–4, depleted through Day 27
B cell nadir reached by Days 3–4, with median B cell counts remaining depleted through Day 27 NKX019 achieved deep B cell depletion at 4B cells/dose, with early evidence of B cell immune reset Naive Memory Plasmablast Early B cell reset in patients with naïve-low baseline in 5 patients Immature Pre-
Slide 23: Key Takeaways – Clinical and Translational Data
Key Takeaways – Clinical and Translational Data Safety Myositis Systemic Sclerosis 5 of 6 (83.3%) patients receiving 4B cells/dose with ≥3 months of follow-up achieved a moderate-to-major TIS response 6 of 7 (85.7%) patients receiving 4B cells/dose achieved rCRISS-25 or higher by Day 90 5 of 7 (71.4
Slide 24: Opportunity & Next Steps
Opportunity & Next Steps nkarta
Slide 25: NKX019: Efficacy and Safety, Made Accessible for Patients and Physicians
NKX019: Efficacy and Safety, Made Accessible for Patients and Physicians Data as of September 18, 2026. Response, safety and endpoint data at the 4 billion cell dose level, in patients with ≥3 months of follow-up. CRS, cytokine release syndrome; GVHD, graft-versus-host disease; ICANS, immune effecto
Slide 26: U.S. market opportunity: patient population
NKX019 Off-the-shelf CD19 CAR NK MYOSITIS Dermatomyositis and antisynthetase syndrome ~7,000 refractory ~80,000 patients SYSTEMIC SCLEROSIS Diffuse cutaneous disease, with or without ILD ~10,000 refractory ~90,000 patients U.S. market opportunity: patient population Preliminary and unrisked market s
Slide 27: Key near-term catalysts and financial position
Key near-term catalysts and financial position Focus on advancing NKX019 in myositis and systemic sclerosis Expected Key Catalysts Upcoming FDA interactions to discuss the registrational path in myositis and systemic sclerosis 1H 2027: Additional follow-up in myositis and systemic sclerosis 1H 2027:
Slide 28: Key near-term catalysts and financial position
Key near-term catalysts and financial position Focus on advancing NKX019 in myositis and systemic sclerosis Expected Key Catalysts Upcoming FDA interactions to discuss the registrational path in myositis and systemic sclerosis 1H 2027: Additional follow-up in myositis and systemic sclerosis 1H 2027: